Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2010
12/14/2010US7851494 administering 5-[(4-(2,6-difluorobenzyloxy)phenyl)-methyl]-1H-tetrazole for the treatment of insulin resistance, diabetes, hyperlipemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis
12/14/2010US7851472 Cyclopropanecarboxylic acid {4-[3-(4-methoxy-phenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-ylamino]-phenyl}-amide; phosphodiesterase inhibitors; neoangiogenesis or inflammatory disease
12/14/2010US7851447 Applying at least one chondroitin sulfate proteoglycan-degrading enzyme to the damaged nerve for promoting repair of a damaged nerve
12/14/2010US7851444 χ-conotoxin peptides (-1)
12/14/2010US7850968 Cluster of differentiation 83 specific immunoglobulin for use in treatment of autoimmune and neoplastic disorders
12/14/2010CA2478811C Tasted masked veterinary solid compositions
12/14/2010CA2438339C Use of buprenorphine for treatment of urinary incontinence
12/14/2010CA2437944C Acylated indanyl amines and their use as pharmaceuticals
12/14/2010CA2433858C Purine derivatives as purinergic receptor antagonists
12/14/2010CA2414787C Coumarin derivatives with comt inhibiting activity
12/14/2010CA2373433C Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
12/14/2010CA2366857C Phthalazine derivatives for treating inflammatory diseases
12/14/2010CA2336781C Hypericin and hypericum extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics
12/14/2010CA2326764C Acylbenzoxazines for enhancing synaptic response(s)
12/14/2010CA2267893C Method and potentiated composition for treating migraine
12/09/2010WO2010141817A1 Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
12/09/2010WO2010141809A1 Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
12/09/2010WO2010141712A2 Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
12/09/2010WO2010141666A2 Modulating endogenous beta-endorphin levels
12/09/2010WO2010141592A2 Chemical fragment screening and assembly utilizing common chemistry for nmr probe introduction and fragment linkage
12/09/2010WO2010141525A1 Active metabolite of a thrombin receptor antagonist
12/09/2010WO2010141505A1 Abuse-resistant delivery systems
12/09/2010WO2010141424A1 Carbamate and urea inhibitors of 11beta-hydroxysteroid dehydrogenase 1
12/09/2010WO2010140716A1 Composition and alcoholic beverage for relieving hangovers and including ornithine or an ornithine salt
12/09/2010WO2010140698A1 Method for induction of differentiation of neural crest cells from pluripotent stem cells
12/09/2010WO2010140694A1 Method for screening of inhibitor using factor capable of enhancing production of amyloid-beta peptide, and inhibitor obtained by same
12/09/2010WO2010140685A1 Heterocyclic compound and hematopoietic stem cell amplifier
12/09/2010WO2010140567A1 Endokinin c/d-origin peptides
12/09/2010WO2010140409A1 Neurite elongation agent, memory-improving agent and anti-alzheimer agent comprising 4'-demethylnobiletin or 4'-demethyltangeretin as active ingredient, and process for production of the compound
12/09/2010WO2010140339A1 Heterocyclic compound
12/09/2010WO2010140271A1 Substance having relaxing activity, concentration-enhancing activity and anti-stress activity
12/09/2010WO2010139758A1 Novel derivatives of aryl-{4-halogeno-4-[aminomethyl]-piperidin-1-yl}-methanone, their method of preparation and their use as medicinal products
12/09/2010WO2010139717A1 New compounds
12/09/2010WO2010139707A1 2-aminooxazolines as taar1 ligands
12/09/2010WO2010139678A1 Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms
12/09/2010WO2010139627A1 New compositions for treating cmt and related disorders
12/09/2010WO2010139483A1 Glycine b antagonists
12/09/2010WO2010139481A1 Glycine b antagonists
12/09/2010WO2010139180A1 Naphthalene carboxamide derivatives as inhibitors of protein kinase and histone deacetylase, preparation methods and uses thereof
12/09/2010WO2010100060A3 Method for increasing endogenous plasmalogen levels in mammals
12/09/2010WO2010089122A3 Vector(s) containing an inducible gene encoding a cdk4/cdk6 inhibitor useful for treating neurodegenerative disorders or diseases associated with an unscheduled activation of the cell cycle
12/09/2010WO2010072807A3 Inhibitors of cystahionine beta synthase for preventing or treating neurotoxic or cognitive disorders
12/09/2010WO2009127944A8 Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors
12/09/2010US20100313285 Altering High Density Lipoprotein Levels Through UDP-N-Acetyl-Alpha-D-Galactosamine: Polypeptide N-Acetlgalactosaminyltransferase (GALNT) Modulation
12/09/2010US20100313283 Uses of gdnf and gdnf receptor
12/09/2010US20100311842 Use of 1-Phenyl-3-dimethylamino-propane Compounds for Treating Neuropathic Pain
12/09/2010US20100311840 Oral formulations of bis(thiohydrazide amides)
12/09/2010US20100311828 Extracts of sclerocarya birrea
12/09/2010US20100311812 RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
12/09/2010US20100311806 Novel polymorphic form of rotigotine and process for production
12/09/2010US20100311803 Method for reducing inflammatory responses and inflammation
12/09/2010US20100311793 Polymorphs of donepezil salts, preparation methods and uses thereof
12/09/2010US20100311792 Benzenesulfonamide Compounds and the Use Thereof
12/09/2010US20100311787 Compounds for inflammation and immune-related uses
12/09/2010US20100311778 Chromane derivatives as trpv3 modulators
12/09/2010US20100311772 Method and compounds for inhibition of cell death
12/09/2010US20100311771 Method of treating movement disorders using barbituric acid derivatives
12/09/2010US20100311769 Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
12/09/2010US20100311767 Method for the treatment of amyloidoses
12/09/2010US20100311755 1,2,4,-triazin-3,5-dione compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
12/09/2010US20100311753 C5aR ANTAGONISTS
12/09/2010US20100311752 Substituted pyridazine derivatives
12/09/2010US20100311749 4-benzoyl-1-substituted-piperazin-2-one derivatives as p2x7 modulators
12/09/2010US20100311745 1,3-dihydroisoindole derivatives
12/09/2010US20100311743 Azaindoles Useful as Inhibitors of Janus Kinases
12/09/2010US20100311741 Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents
12/09/2010US20100311736 Pyridosulfonamide derivatives as p13 kinase inhibitors
12/09/2010US20100311734 Spiro Compounds Useful as Antagonists of the H1 Receptor
12/09/2010US20100311732 Novel heterocyclic compounds
12/09/2010US20100311728 Manipulation of brain CDP-diacylglycerol and uses thereof
12/09/2010US20100311727 Therapeutic amine-arylsulfonamide conjugate compounds
12/09/2010US20100311726 Reduction of beta-amyloid levels by treatment with the small molecule differentiation-inducing factor
12/09/2010US20100311725 Noribogaine in the treatment of pain and drug addiction
12/09/2010US20100311724 Noribogaine in the treatment of pain and drug addiction
12/09/2010US20100311723 Noribogaine in the treatment of pain and drug addiction
12/09/2010US20100311722 Noribogaine in the treatment of pain and drug addiction
12/09/2010US20100311720 Spiroindoline Modulators of Muscarinic Receptors
12/09/2010US20100311719 Prevention of Obesity in Antipsychotic, Antidepressant and Antiepileptic Medication
12/09/2010US20100311718 Treatment of Psychoses with Dibenzothiazepine Antipsychotic
12/09/2010US20100311717 Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs
12/09/2010US20100311711 Inhibitors of NAAA and Methods Thereof
12/09/2010US20100311710 Cyclobutanemethanamine inhibitors of monoamine reuptake
12/09/2010US20100311709 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS
12/09/2010US20100311704 Pharmaceutical delivery systems for treatment of substance abuse and other addictions
12/09/2010US20100311703 New compounds as adenosine a1 receptor antagonists
12/09/2010US20100311699 Novel carboxylic acid 4-phenylazo-phenyl ester derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
12/09/2010US20100311697 Methods and Compositions for the Treatment of CNS-Related Conditions
12/09/2010US20100311692 Pharmaceutical Formulation Containing Choline Alfoscerate
12/09/2010US20100311682 Antimelancholic medicine prepared with jujube camp materials
12/09/2010US20100311674 Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression
12/09/2010US20100311665 Method and Composition for Potentiating an Opiate Analgesic
12/09/2010US20100311664 Methods for reducing oxidative damage
12/09/2010US20100311663 Memory influencing protein
12/09/2010US20100311655 Intranasal carbetocin formulations and methods for the treatment of autism
12/09/2010US20100311653 Splice variants of gdnf and uses thereof
12/09/2010US20100311651 Use of glp-1 compound for treatment of critically ill patients
12/09/2010US20100311648 Melanocortin receptor-specific peptides
12/09/2010US20100311643 Use of glp-1 as a therapeutic agent
12/09/2010US20100311639 Inhibitors of ncca-atp channels for therapy
12/09/2010US20100311189 Novel Receptor Nucleic Acids and Polypeptides
1 ... 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 ... 1833